Biotest AG
Develops and supplies plasma protein products and biotherapeutic drugs from human plasma.
BIO3 | F
Overview
Corporate Details
- ISIN(s):
- DE0005227201 (+1 more)
- LEI:
- 529900JVX7RPXBLYUD89
- Country:
- Germany
- Address:
- Landsteinerstraße 5, 63303 Dreieich
- Sector:
- Manufacturing
Description
Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-01 00:00 |
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2025 bis zum 31.12.2025
|
German | 9.6 KB | ||
| 2025-11-13 10:07 |
Biotest obtains approval for new human fibrinogen Prufibry in Germany
|
English | 10.7 KB | ||
| 2025-11-07 15:19 |
Biotest AG: Extraordinary general meeting convened again at the request of Grif…
|
English | 7.0 KB | ||
| 2025-10-23 13:16 |
Biotest AG: Cancellation of the extraordinary general meeting on 28 October 2025
|
English | 6.0 KB | ||
| 2025-10-09 17:30 |
Biotests Yimmugo launches in the United States
|
English | 7.4 KB | ||
| 2025-09-19 15:00 |
Biotest AG: Extraordinary general meeting convened at the request of Grifols S.…
|
English | 6.3 KB | ||
| 2025-09-17 00:00 |
Articles of association - as of July 02, 2025
|
English | 133.4 KB | ||
| 2025-08-04 13:00 |
Biotest AG receives a request from Grifols S.A. to convene an extraordinary gen…
|
English | 6.8 KB | ||
| 2025-07-02 18:08 |
Biotest AG: Annual General Meeting approves dividend distribution
|
English | 7.8 KB | ||
| 2025-06-23 17:03 |
Biotests positive fibrinogen phase III trial results published in The Lancets e…
|
English | 14.5 KB | ||
| 2025-06-20 00:00 |
Berichtigung der Veröffentlichung vom 17.04.2025
|
German | 303.6 KB | ||
| 2025-06-03 16:51 |
Biotest AG: Delisting of Biotest shares from the Frankfurt Stock Exchange with …
|
English | 8.2 KB | ||
| 2025-05-28 17:00 |
Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
|
English | 8.1 KB | ||
| 2025-05-12 17:35 |
Biotest confirms Guidance for 2025
|
English | 11.5 KB | ||
| 2025-05-12 00:00 |
Q1 statement / Q1 financial report 2025
|
English | 414.7 KB |
Automate Your Workflow. Get a real-time feed of all Biotest AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biotest AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biotest AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-11-29 | Bernöster, Dr. Katrin | Other | Sell | None | 15,640.00 EUR |
| 2021-11-29 | Realsoul Holding S.A. | Close relation | Buy | None | 1,713.60 EUR |
| 2021-11-18 | Fleck, Stephan | Other | Sell | None | 120,870.00 EUR |
| 2021-11-18 | Schüttrumpf, Dr. Jörg | Other | Sell | None | 99,895.50 EUR |
| 2021-11-18 | Reinecke, Dr. Martin | Other | Sell | None | 37,715.00 EUR |
| 2021-11-18 | Moritz, Michael | Other | Sell | None | 35,460.00 EUR |
Peer Companies
